Skip to main content
OpenTrials
Completed

NCT Number: NCT07046520

Effects of HIIT on Plasma Volume and Aerobic Capacity in Obese Adolescent Girls

The goal of this clinical trial is to investigate the impact of high-intensity interval training (HIIT) program on body composition, hematological parameters, plasma volume variations (PVV), muscle damage markers, and aerobic capacity in overweight/obese adolescent girls. The main question it aims to answer is: Does HIIT reduce risk factors associated obesity diseases by modulating body composition and hematological parameters and increasing PVV? Researchers will compare HIIT (designed to the experimental group) to nontraining intervention (designed to the control group) to see if the training program works to enhance physiological health and reduce risk factors associated with obesity in this population. Participants in the experimental (HIIT group) group will: underwent HIIT at 90-105% maximal aerobic speed (MAS), three times a week.

Participants in control group will : not perform any physical training and maintain their usual daily activities.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematologic Test Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

15 year–17 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

High Institute of Sports and Physical Education of Kef

El Kef, Boulifa, 7100, Tunisia

About this study

Obesity during adolescence is linked to adverse changes in body composition, aerobic fitness, and blood health. High-intensity interval training (HIIT) is a promising strategy to improve these outcomes. However, its effects on hematological markers, plasma volume, and muscle damage in overweight/obese adolescent girls remain unclear. This study aimed to investigate the effects of HIIT on body composition, hematological parameters, plasma volume variations (PVV), muscle damage markers, and aerobic capacity in this population.Twenty-eight overweight/obese girls (16.21±0.92) were randomly assigned to a HIIT group (n=14) or control group (n=14). The 10-week HIIT protocol consisted of 4×6×15s running at 90-105% maximal aerobic speed (MAS) with 15s of active recovery at 50% MAS (3 sessions/week). Pre/post assessments included body composition, hematological markers, muscle damage markers, and aerobic fitness. Plasma volume was estimated post-intervention in both group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females.
  • Aged between 15 and 17 years.
  • BMI greater than or equal to the 95th percentile for their age.

Exclusion criteria

  • Pharmacological treatments or medical conditions that could interact with the protocol (e.g.,hypertension, diabetes, cardiac, orthopedic, neuromuscular, or neurological disorders).
  • Hormone replacement therapy or therapies for obesity.
  • Irregular menstrual cycle.
  • Restrictive diet or use of dietary supplements or engagement in any structured physical training either currently or during the previous three months.
  • Withdrawal of consent.
  • Non-compliance with study procedures.
  • Insufficient data for analysis.

Treatment and study plan

High Intensity Interval Training

Behavioral

HIIT protocol was performed three times per week over a 10-week period, totaling 30 sessions. HIIT sessions included: (1) a standardized warm-up of five minutes of continuous jogging at 50%MAS, followed by five minutes of dynamic mobility and activation drills such as high-knee skips, high-knee running, and butt kicks. (2) a HIIT training session, consisted of four series of 15-second runs at 90-105% of the maximal aerobic speed (MAS) interspersed with 15 seconds of active recovery and (3) a cool-down of five minutes of static stretching.

Primary outcomes

  1. Erythrocytes

    Time frame: At baseline and at week 11 (end of intervention period).

    Blood levels of erythrocytes were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany).

  2. Hemoglobin

    Time frame: At baseline and at week 11 (end of intervention period).

    Blood levels of hemoglobin were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany).

  3. Hematocrit

    Time frame: At baseline and at week 11 (end of intervention period).

    Blood levels of hematocrit were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany).

  4. Mean corpuscular volume

    Time frame: At baseline and at week 11 (end of intervention period).

    Blood levels of mean corpuscular volume were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany).

  5. Mean corpuscular hemoglobin content

    Time frame: At baseline and at week 11 (end of intervention period).

    Blood levels of mean corpuscular hemoglobin content were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany).

  6. Mean hemoglobin concentration

    Time frame: At baseline and at week 11 (end of intervention period)

    Blood levels of mean hemoglobin concentration were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany).

  7. Creatine kinase

    Time frame: At baseline and at week 11 (end of intervention period).

    Serum concentrations of creatine kinase are measured from a blood sample (5 ml) using a Beckman Coulter AU480 Chemistry Analyzer (France).

  8. Lactate dehydrogenase

    Time frame: At baseline and at week 11 (end of intervention period).

    Serum concentrations of lactate dehydrogenase are measured from a blood sample (5 ml) using a Beckman Coulter AU480 Chemistry Analyzer (France).

  9. Plasma volume variations

    Time frame: Plasma volume variations (PVV) was calculated at week 11 (end of intervention period) under two conditions (High intensity interval training and No training intervention [control group] ).

    Plasma volume variations (PVV) was calculated based on measured hematocrit (Ht) and hemoglobin (Hb) values according to the method developed by Costill and Fink (1974). %PVV=100 ×[(HbA/HbB) ×(100 - HtB) / (100 - HtA)] - 1, where 0 is the value measured before training program and 1 is the value measured after training program.

  10. Body weight

    Time frame: At baseline and at week 11 (end of intervention period).

    Body weight (kg) was recorded , with barefoot and lightly dressed subjects, using an electronic scale (Tanita BC-533, Tokyo, Japan).

  11. Height

    Time frame: At baseline

    Height (m) was determined using a standard stadiometer (Holtain Ltd., UK).

  12. Body fat

    Time frame: At baseline and at week 11 (end of intervention period)

    Body fat (%) was recorded using an electronic scale (Tanita BC-533, Tokyo, Japan).

  13. Body mass index

    Time frame: At baseline and at week 11 (end of intervention period).

    Body mass index (kg/m²) was calculated as weight (kg) divided by height squared (m²).

  14. Waist circumference

    Time frame: At baseline and at week 11 (end of intervention period).

    Waist circumference (cm) was measured to the nearest 0.1 cm using a non-deformable anthropometric tape, placed horizontally at the midpoint between the inferior margin of the last palpable rib and the superior border of the iliac crest, with the participant standing upright and breathing normally.

  15. Maximal aerobic speed

    Time frame: At baseline and at week 11 (end of intervention period).

    Maximal aerobic speed was determined using the Vameval test (Cazorla,1990).

  16. Maximal oxygen consumption (VO2max)

    Time frame: At baseline and at week 11 (end of intervention period).

    Maximal oxygen consumption (VO2max) were determined using the Vameval test (Cazorla,1990).

  17. Maximal heart rate (HRmax)

    Time frame: At baseline and at week 11 (end of intervention period).

    Maximal heart rate maximum (HRmax) was recorded at the final stage of the Vameval test (Cazorla,1990) using a Polar heart rate monitor (Polar S810, Kempele, Finland).

Sponsors and collaborators

Lead sponsor

High Institute of Sports and Physical Education of Kef

Other

Registry information

Official study title

Effects of High-Intensity Interval Training on Plasma Volume, Muscle Damage, and Aerobic Performance in Overweight Adolescent Females

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 1, 2025
Registry last updated
Jul 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.